🇪🇺 ABP 710 in European Union

ABP 710 (ABP 710) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005020
  • Marketing authorisation holder: Amgen Europe B.V.
  • Local brand name: ABP 710
  • Indication: Treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative colitis
  • Status: withdrawn

Read official source →

Other Immunology / Rheumatology approved in European Union

Frequently asked questions

Is ABP 710 approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for ABP 710 in European Union?

Amgen Europe B.V. holds the EU marketing authorisation.